GlaxoSmithKline Pharmaceuticals Ltd. - Research Center
500660 GLAXO Group (A) BSE data
Add to watchlist
| Results |
Quarterly
|
| Statement | |
| More |
Quarterly results in brief
(Rs crore)
| Sep' 20 | Jun' 20 | Mar' 20 | Dec' 19 | Sep' 19 | |
|---|---|---|---|---|---|
| Sales | 879.39 | 648.65 | 775.88 | 778.68 | 882.10 |
| Operating profit | 205.02 | 114.35 | 174.08 | 124.65 | 194.24 |
| Interest | 0.88 | 1.08 | 1.51 | 2.98 | 0.92 |
| Gross profit | 213.06 | 171.06 | 187.73 | 137.92 | 208.93 |
| EPS (Rs) | 4.52 | 6.55 | 8.14 | -38.02 | 29.68 |
Quarterly
results in details
| Sep' 20 | Jun' 20 | Mar' 20 | Dec' 19 | Sep' 19 | |
|---|---|---|---|---|---|
| Other income | 8.92 | 57.79 | 15.16 | 16.25 | 15.61 |
| Stock adjustment | -25.01 | 2.19 | -20.15 | -23.34 | 145.26 |
| Raw material | 145.61 | 106.72 | 98.33 | 112.45 | 94.56 |
| Power and fuel | - | - | - | - | - |
| Employee expenses | 154.01 | 151.92 | 171.58 | 166.69 | 147.47 |
| Excise | - | - | - | - | - |
| Admin and selling expenses | - | - | - | - | - |
| Research and development expenses | - | - | - | - | - |
| Expenses capitalised | - | - | - | - | - |
| Other expenses | 399.76 | 273.47 | 352.04 | 398.23 | 300.57 |
| Provisions made | - | - | - | - | - |
| Depreciation | 21.96 | 21.77 | 22.59 | 18.33 | 22.70 |
| Taxation | 50.47 | 38.33 | 38.47 | 26.83 | 84.58 |
| Net profit / loss | 76.50 | 110.96 | 137.94 | -644.14 | 502.79 |
| Extra ordinary item | -64.13 | - | 11.27 | -736.90 | 401.14 |
| Prior year adjustments | - | - | - | - | - |
| Equity capital | 169.41 | 169.41 | 169.41 | 169.41 | 169.41 |
| Equity dividend rate | - | - | - | - | - |
| Agg.of non-prom. shares (Lacs) | - | - | - | - | - |
| Agg.of non promotoholding (%) | - | - | - | - | - |
| OPM (%) | 23.31 | 17.63 | 22.44 | 16.01 | 22.02 |
| GPM (%) | 23.98 | 24.21 | 23.73 | 17.35 | 23.27 |
| NPM (%) | 8.61 | 15.71 | 17.44 | -81.03 | 56.01 |
Mutual Fund Selector
Find the fund that is right for you
© 2020 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis